All articles by Urtė Fultinavičiūtė

Urtė Fultinavičiūtė is a healthcare reporter for Clinical Trials Arena. Urtė's coverage focuses on clinical data management and clinical strategy. Urtė holds an MA in International Journalism from City, University of London.

Urtė Fultinavičiūtė


Medicenna to expand Phase III glioblastoma trial globally

Medicenna is also starting to enrol patients in an ongoing Phase I/II trial in solid tumours investigating dose expansion of MDNA11.

Pain points: Unsolved recruitment and trial design issues in pain clinical trials

Although pain affects millions of people worldwide, the industry is still struggling in the ongoing search for safe and effective medication.

Boundless Bio collaborates with Lilly for Phase I/II solid tumour trial

The first-in-human trial will investigate Boundless Bio’s BBI-355 as a single agent and in combination with targeted therapies.

Lipocine gears up for two pivotal trials in 2023/2024

Lipocine plans to initiate two registrational trials with LPCN 1148 in cirrhosis and LPCN 1154 in postpartum depression.

Nektar recalculates new efficacy data for rezpegaldesleukin in AD

After accusing its former partner, Nektar bounces back with new planned trials in AD and alopecia areata.

Merck releases new data on sotatercept in PAH

Merck presented new post-hoc and long-term data analyses further showing sotatercept’s safety and efficacy in PAH.

Kodiak’s shelved tarcocimab succeeds in RVO trial

After a recent flop in another ophthalmology indication, Kodiak’s tarcocimab demonstrated matched efficacy and durability signals in RVO.

Q&A: Importance of human touch in patient experience and clinical trial participation

Kuno van der Post, chief revenue officer at Meeting Protocol Worldwide, discusses why human interaction remains crucial in clinical trials.

Synchron completes enrolment in neural interface technology trial

The early feasibility study will investigate the safety of BCI device implantation and its efficacy for daily digital tasks in patients with paralysis.

Oncorena treats first renal cancer patient with ONC175 in Phase I/II trial

More renal cancer patients are expected to be treated with ONC175 in the upcoming months, with possible expansion to other countries.